19 297

Cited 23 times in

Low-molecular-weight heparin versus unfractionated heparin in acute ST-segment elevation myocardial infarction patients undergoing primary percutaneous coronary intervention with drug-eluting stents.

Authors
Li, YJ; Rha, SW; Chen, KY; Poddar, KL; Jin, Z; Minami, Y; Wang, L; Dang, Q; Li, GP; Ramasamy, S; Park, JY; Choi, CU; Kim, JW; Kim, EJ; Park, CG; Seo, HS; Oh, DJ; Jeong, MH; Ahn, YK; Hong, TJ; Park, JS; Kim, YJ; Hur, SH; Seong, IW; Chae, JK; Cho, MC; Bae, JH; Choi, DH; Jang, YS; Chae, IH; Kim, HS; Kim, CJ; Yoon, JH; Ahn, TH; Tahk, SJ; Chung, WS; Seung, KB; Park, SJ
Citation
American heart journal, 159(4):684-690.e1, 2010
Journal Title
American heart journal
ISSN
0002-87031097-6744
Abstract
BACKGROUND: Whether low-molecular-weight heparin (LMWH) is superior to unfractionated heparin (UFH) in acute ST-segment elevation myocardial infarction (STEMI) patients undergoing primary percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) remains unclear. METHODS: A total of 3,372 STEMI patients who underwent primary PCI with DESs received either LMWH (n = 1,531 patients, subcutaneous enoxaparin 1 mg/kg, bid for 3-5 days plus reduced dose of UFH [50 U/kg] during PCI) or UFH alone (n = 1,841 patients, intravenous bolus injection of 5,000 U, followed by 24,000 U/d infusion for at least 48 hours). The bleeding events and clinical outcomes during in-hospital and at 8 months were compared. RESULTS: The incidences of major and minor bleeding events were similar between the 2 groups. Multivariable Cox regression analysis showed that LMWH group had lower incidences of cardiac death (adjusted odds ratio [OR] 0.55, 95% CI 0.39-0.77, P < .001), total death (adjusted OR 0.50, 95% CI 0.37-0.68, P < .001), and total major adverse cardiac events (adjusted OR 0.77, 95% CI 0.62-0.95, P = .017) at 8 months as compared with UFH group. Similar results were obtained across different subgroups including different DESs, age, and sex. CONCLUSIONS: The LMWH enoxaparin combined with reduced dose of UFH (50 U/kg) administration as an adjunctive antithrombotic therapy in STEMI patients undergoing primary PCI with DESs seems to be safe and efficacious. However, randomized clinical trials are needed to confirm this conclusion.
MeSH terms
Aged*Angioplasty, Balloon, CoronaryAnticoagulants/*administration & dosageDrug Therapy, CombinationDrug-Eluting StentsElectrocardiographyEnoxaparin/*administration & dosageFemaleHumansMaleMiddle AgedMyocardial Infarction/drug therapy/*therapyTreatment Outcome
DOI
10.1016/j.ahj.2009.12.041
PMID
20362730
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Cardiology
AJOU Authors
탁승제
Full Text Link
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse